Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects
- 1 March 2015
- journal article
- review article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 3 (2) , 167-174
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Novel targeted therapies for eosinophilic disordersJournal of Allergy and Clinical Immunology, 2012
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEuropean Respiratory Journal, 2012
- IL-5 receptor α levels in patients with marked eosinophilia or mastocytosisJournal of Allergy and Clinical Immunology, 2011
- Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndromeJournal of Allergy and Clinical Immunology, 2010
- Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitisJournal of Allergy and Clinical Immunology, 2010
- Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapyJournal of Allergy and Clinical Immunology, 2009
- Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptorsClinical & Experimental Allergy, 2009
- Eosinophil granules function extracellularly as receptor-mediated secretory organellesProceedings of the National Academy of Sciences, 2008
- Anti-IgE treatment of eosinophil-associated gastrointestinal disordersJournal of Allergy and Clinical Immunology, 2007
- Disruption of the murine IL-4 gene blocks Th2 cytokine responsesNature, 1993